Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.
about
MHC Class II-Restricted Epitopes Containing an Oxidoreductase Activity Prompt CD4(+) T Cells with Apoptosis-Inducing PropertiesCharacteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.Autoreactive effector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage.CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production.A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific mannerInflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes.Environmental Basis of Autoimmunity.Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Harnessing nanoparticles for immune modulationControlled release strategies for modulating immune responses to promote tissue regenerationThioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model.Mechanistic basis of immunotherapies for type 1 diabetes mellitusPLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes.Transient B-cell depletion combined with apoptotic donor splenocytes induces xeno-specific T- and B-cell tolerance to islet xenografts.Exploiting apoptosis for therapeutic tolerance induction.Autoantigen-induced focusing of Vβ13+ T cells precedes onset of autoimmune diabetes in the LEW.1WR1 rat.Inducing immune tolerance: a focus on Type 1 diabetes mellitus.Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes.Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.Virus infection, antiviral immunity, and autoimmunity.Self-antigen expression in the peripheral immune system: roles in self-tolerance and type 1 diabetes pathogenesis.Guiding principles in the design of molecular bioconjugates for vaccine applications.Immunotherapies currently in development for the treatment of type 1 diabetes.Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Regulatory T cell-based therapies for autoimmunity.In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs.T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells.Thyroid Autoantibodies Display both “Original Antigenic Sin” and Epitope Spreading.Type 1 diabetes induction in humanized mice.Modifying Enzymes are Elicited by ER Stress, Generating Epitopes that are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.Humoral Epitope Spreading in Autoimmune Bullous Diseases.
P2860
Q26782899-61A01094-5AE3-406A-BA8A-F9022EAB7920Q33408423-D5EF57FE-5066-496B-8CAC-5EBAB0453561Q34375578-A7F74F9B-5A30-4A75-83A5-CABDAD742FE5Q34517586-D4BB5873-DC18-4EC0-8F58-6FE84F22D14CQ34803518-1492CCBC-6AE5-4FAF-A625-521E0D396E9AQ34972123-4B03DC70-A3EF-4A29-8715-B9C846B7DD52Q35004357-3BD20210-E1CB-48B7-B513-75C898F6A160Q35638839-8001C0D4-9898-44C7-AAF8-F9F263D0BD85Q36011368-1F42BA4E-46FC-4F77-81DF-D30555E2238DQ36154772-42AB631D-4E12-4A74-9747-CAB0096FF23CQ36307642-10903162-64FC-489B-A08C-48D0ED36B97FQ36637650-7A6EC92A-3469-4347-94DD-EA97241B4658Q36698793-0D3EA0F1-0B1D-4B18-BAC8-AEF2E33E66FFQ36801593-792EDD76-C46E-470B-A4D3-343B76A06DB9Q37110633-7C6D1ADA-8C6B-4BC1-8C46-7FBEC5C3D1ACQ37353657-8E0FEE80-8D43-4DC2-B229-158F9EF2F1E9Q37510173-4F82F590-54AF-447C-82C6-8714509630B0Q37542678-17ADDE36-384B-4EBA-A149-31AFECEA0187Q37599880-E96B295C-41A8-4DDF-A97B-038F83E6F6EDQ38117283-C29B5527-ABB5-4766-9114-173E7EDB3FC0Q38129086-A0B3F355-E5E0-4B49-8980-C89A4E92F1AFQ38230215-BE233F28-50A1-4944-AC7A-B84073074E9DQ38395963-6EA60853-8F13-433D-9483-95718A738009Q38585822-442E1181-6ACC-47EA-BC5C-4CF337A4B0A9Q38645059-B91709E7-ADB4-4811-8884-49A01DB74C79Q38943933-22BD50D5-7F8C-4ABC-880F-3C9F6F9D67EFQ39245827-CDE4E10C-4A43-4365-A6F7-DC768673AB9EQ40895314-64BD604D-57B8-49E6-A76F-4EE4A34E8FE7Q47093542-436AA5AE-2DEB-4CD6-AE34-E8198BB270FFQ47219879-A0118536-46FF-45CE-BA15-69A0F9D36007Q47234002-9EC069DC-4F9A-437E-A7EF-FC638E7FC67AQ47412579-411A5511-6ED5-489A-BA29-CBAA864BF430Q47569628-3C490255-95B2-4143-8566-743EA34E0552Q52719485-6651DE1E-E427-48CD-89D3-C11F01CA3785Q55262188-57AB1A24-CAA4-49DD-A0F6-87AC6C7DFBAD
P2860
Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pathogenesis of NOD diabetes i ...... functional epitope spreading.
@ast
Pathogenesis of NOD diabetes i ...... functional epitope spreading.
@en
type
label
Pathogenesis of NOD diabetes i ...... functional epitope spreading.
@ast
Pathogenesis of NOD diabetes i ...... functional epitope spreading.
@en
prefLabel
Pathogenesis of NOD diabetes i ...... functional epitope spreading.
@ast
Pathogenesis of NOD diabetes i ...... functional epitope spreading.
@en
P2093
P2860
P1476
Pathogenesis of NOD diabetes i ...... functional epitope spreading.
@en
P2093
Adam P Kohm
Jeffrey S McMahon
Stephen D Miller
Suchitra Prasad
Xunrong Luo
P2860
P304
P356
10.1016/J.JAUT.2012.04.005
P577
2012-05-28T00:00:00Z